Multidrug-resistant Tuberculosis

Medical Clinics of North America

Volumn 97, Issue 4, 2013, Pages 553-579

  Lynch, John B ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Drug resistance; Drug susceptibility testing; HIV AIDS; Tuberculosis

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMINOSALICYLIC ACID; BEDAQUILINE; CAPREOMYCIN; CLARITHROMYCIN; CYCLOSERINE; DELAMANID; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; NITRATE REDUCTASE; OFLOXACIN; PYRAZINAMIDE; PYRIDOXINE; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE;

ADULT; BACTERIOSTASIS; COUGHING; DECREASED APPETITE; DIRECTLY OBSERVED THERAPY; DNA EXTRACTION; DRUG SENSITIVITY; EMPYEMA; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FATIGUE; FEVER; FISTULA; GENE SEQUENCE; HEMOPTYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INFECTION CONTROL; INFECTION PREVENTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NIGHT SWEAT; NUCLEIC ACID AMPLIFICATION; PNEUMOTHORAX; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SPUTUM CULTURE; SPUTUM SMEAR; TUBERCULOUS LYMPHADENITIS; TURNAROUND TIME; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ANTITUBERCULAR AGENTS; DEVELOPING COUNTRIES; HUMANS; INFECTION CONTROL; MICROBIAL SENSITIVITY TESTS; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH;

EID: 84879730069     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2013.03.012     Document Type: Review

References (194)

1. Skrahina A., Hurevich H., Zalutskaya A. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull World Health Organ 2013, 91(1):36-45.
2. Centers for Disease Control and Prevention (CDC) Interruptions in supplies of second-line antituberculosis drugs - United States, 2005-2012. MMWR Morb Mortal Wkly Rep 2013, 62:23-26.
3. Hirsch-Moverman Y., Daftary A., Franks J., et al. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int JTuberc Lung Dis 2008, 12:1235-1254.
4. Lalloo U.G., Pillay S. Managing tuberculosis and HIV in sub-Sahara Africa. Curr HIV/AIDS Rep 2008, 5:132-139.
5. Crofton J., Mitchison D.A. Streptomycin resistance in pulmonary tuberculosis. Br Med J 1948, 2:1009-1015.
6. Keshavjee S., Farmer P.E. Tuberculosis, drug resistance, and the history of modern medicine. NEngl J Med 2012, 367:931-936.
7. Iseman M.D. Tailoring a time-bomb. Inadvertent genetic engineering. Am Rev Respir Dis 1985, 132:735-736.
8. Cegielski J.P. Extensively drug-resistant tuberculosis: "there must be some kind of way out of here". Clin Infect Dis 2010, 50(Suppl 3):S195-S200.
9. Bhullar K., Waglechner N., Pawlowski A., et al. Antibiotic resistance is prevalent in an isolated cave microbiome. PLoS One 2012, 7:e34953.
10. Wright G.D., Poinar H. Antibiotic resistance is ancient: implications for drug discovery. Trends Microbiol 2012, 20:157-159.
11. D'Costa V.M., et al. Antibiotic resistance is ancient. Nature 2011, 477:457-461.
12. Lederberg J. Infectious history. Science 2000, 288:287-293.
13. Dye C., Lönnroth K., Jaramillo E. Trends in tuberculosis incidence and their determinants in 134 countries. Bull World Health Organ 2009, 87(9):683-691.
14. Raviglione M., et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 2012, 379:1902-1913.
15. Keshavjee S., et al. Treating multidrug-resistant tuberculosis in Tomsk, Russia: developing programs that address the linkage between poverty and disease. Ann N Y Acad Sci 2008, 1136:1-11.
16. Mitnick C., et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. NEngl J Med 2003, 348:119-128.
17. WHO Global tuberculosis report 2012 2012, World Health Organization, Geneva (Switzerland).
18. Daniel T.M. The history of tuberculosis. Respir Med 2006, 100:1862-1870.
19. Smith D.G., Waksman S.A. Tuberculostatic and tuberculocidal action of streptomycin. J Bacteriolo 1947, 54(1):67.
20. McDougall J.B. Streptomycin and tuberculous meningitis. Br Med J 1948, 1(4540):74.
21. Velu S., et al. Acontrolled comparison of streptomycin plus pyrazinamide and streptomycin plus PAS in the retreatment of patients excreting isoniazid-resistant organisms. Tubercle 1964, 45:144-159.
22. Kristenson A. Treatment of cavernous pulmonary tuberculosis with a combination of chemotherapy and antibiotics. Acta Tuberc Scand Suppl 1950, 26:15-25.
23. Fox W., Ellard G.A., Mitchison D.A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999, 3:S231-S279.
24. Selikoff I.J., Robitzek E.H., Ornstein G.G. Treatment of pulmonary tuberculosis with hydrazide derivatives of isonicotinic acid. JAm Med Assoc 1952, 150:973-980.
25. Manten A., Van Wijngaarden L.J. Development of drug resistance to rifampicin. Chemotherapy 1969, 14:93-100.
26. Conway H. Prevalence of drug resistance in previously untreated patients United States Public Health Service Cooperative Investigation. Am Rev Respir Dis 1964, 89:327-336.
27. Hobby G.L. Primary drug resistance in tuberculosis. A review. I. Am Rev Respir Dis 1962, 86:839-846.
28. Steiner M., Cosio A. Primary tuberculosis in children. 1. Incidence of primary drug-resistant disease in 332 children observed between the years 1961 and 1964 at the Kings County Medical Center of Brooklyn. NEngl J Med 1966, 274:755-759.
29. Sen A. Fertility and coercion. Univ Chic Law Rev 2007, 63:1035-1061.
30. Steiner P., Rao M., Victoria M.S., et al. Acontinuing study of primary drug-resistant tuberculosis among children observed at the Kings County Hospital Medical Center between the years 1961 and 1980. Am Rev Respir Dis 1983, 128:425-428.
31. Chaves A.D., Dangler G., Abeles H., et al. The prevalence of drug resistance among strains of M. tuberculosis isolated from ambulatory patients in New York City. Am Rev Respir Dis 1961, 84:744-745.
32. Hershfield E.S., Eidus L., Helbecque D.M. Canadian survey to determine the rate of drug resistance to isoniazid, PAS and streptomycin in newly detected untreated tuberculosis patients and retreatment cases. Int J Clin Pharmacol Biopharm 1979, 17:387-393.
33. Hurley J.C., Uren E.M., Andrew J.H., et al. Culture-positive tuberculosis at St Vincent's Hospital, Melbourne, 1962-1989. Aust N Z J Med 1993, 23:7-11.
34. Janowiec M., Zwolska-Kwiek Z., Bek E. Drug resistance in newly discovered untreated tuberculosis patients in Poland, 1974-1977. Tubercle 1979, 60:233-237.
35. Tsukamura M. Annual change of drug resistance cases viewed through a Japanese National Sanatorium. Acta Tuberc Pneumol Scand 1964, 45:149-153.
36. Pines A., Richardson R.J. Drug-resistance in patients with pulmonary tuberculosis presenting at chest clinics in Hong Kong. Tubercle 1964, 45:77-95.
37. Pepys J., Mitchison D.A., Kinsley B.J. The prevalence of bacterial resistance to isoniazid and to PAS in patients with acute pulmonary tuberculosis presenting for treatment in East Africa. Tubercle 1960, 41:32-36.
38. Cantwell M.F., Snider D.E., Cauthen G.M., et al. Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA 1994, 272:535-539.
39. Brudney K., Dobkin J. Resurgent tuberculosis in New York City. Human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis 1991, 144:745-749.
40. Barnes P.F., Bloch A.B., Davidson P.T., et al. Tuberculosis in patients with human immunodeficiency virus infection. NEngl J Med 1991, 324:1644-1650.
41. Cantwell M.F., McKenna M.T., McCray E., et al. Tuberculosis and race/ethnicity in the United States: impact of socioeconomic status. Am J Respir Crit Care Med 1998, 157:1016-1020.
42. Frieden T.R., Sterling T., Pablos-Mendez A. The emergence of drug-resistant tuberculosis in New York City. NEngl J Med 1993, 328(8):521-526.
43. Pearson M.L., et al. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis. A risk to patients and health care workers. Ann Intern Med 1992, 117:191-196.
44. McKenna M.T., McCray E., Jones J.L., et al. The fall after the rise: tuberculosis in the United States, 1991 through 1994. Am J Public Health 1998, 88:1059-1063.
45. CDC Reported tuberculosis in the United States, 2011 2011, Center for Disease Control and Prevention, Atlanta (GA).
46. Dalton T., et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012, 380:1406-1417.
47. Centers for Disease Control (CDC) Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons-Florida and New York, 1988-1991. MMWR Morb Mortal Wkly Rep 1991, 40:585-591.
48. Centers for Disease Control (CDC) Tuberculosis outbreak among persons in a residential facility for HIV-infected persons-San Francisco. MMWR Morb Mortal Wkly Rep 1991, 40:649-652.
49. From the Centers for Disease Control. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons-Florida and New York, 1988-1991. JAMA 1991, 266:1483-1485.
50. WHO TB. A global emergency 1994, World Health Organization, Geneva (Switzerland).
51. Watts G. WHO annual report finds world at a crossroad on tuberculosis. BMJ 2012, 345:e7051.
52. Mukadi Y.D., Maher D., Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 2001, 15:143-152.
53. Huffman S.A., Veen J., Hennink M.M., et al. Exploitation, vulnerability to tuberculosis and access to treatment among Uzbek labor migrants in Kazakhstan. Soc Sci Med 2012, 74:864-872.
54. Long Q., et al. Barriers to accessing TB diagnosis for rural-to-urban migrants with chronic cough in Chongqing, China: a mixed methods study. BMC Health Serv Res 2008, 8:202.
55. Storla D.G., Yimer S., Bjune G.A. Asystematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health 2008, 8:15.
56. WHO Toward universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015 2011, World Health Organization, Geneva (Switzerland).
57. Skrahina A., et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012, 39:1425-1431.
58. Zhao Y., et al. National survey of drug-resistant tuberculosis in China. NEngl JMed 2012, 366:2161-2170.
59. He G.X., et al. Multidrug-resistant tuberculosis, People's Republic of China, 2007-2009. Emerg Infect Dis 2011, 17:1831-1838.
60. Liu C.H., et al. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience. PLoS One 2011, 6(4):e19399.
61. Becerra M.C., et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet 2011, 377:147-152.
62. Minion J., Gallant V., Wolfe J., et al. Multidrug and extensively drug-resistant tuberculosis in Canada 1997-2008: demographic and disease characteristics. PLoS One 2013, 8:e53466.
63. Hoa N.B., et al. National survey of tuberculosis prevalence in Viet Nam. Bull World Health Organ 2010, 88:273-280.
64. Lawn S.D., Zumla A.I. Tuberculosis. Lancet 2011, 378:57-72.
65. Magee M.J., et al. Prevalence of drug resistant tuberculosis among patients at high-risk for HIV attending outpatient clinics in Delhi, India. Southeast Asian JTrop Med Public Health 2012, 43:354-363.
66. Zhang Y., Yew W.W. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009, 13:1320-1330.
67. Caws M., Ha D.T. Scale-up of diagnostics for multidrug resistant tuberculosis. Lancet Infect Dis 2010, 10:656-658.
68. Martin A., et al. The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. JAntimicrob Chemother 2008, 62:56-64.
69. Canetti G., Rist N., Grosset J. Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation. Rev Tuberc Pneumol (Paris) 1963, 27:217-272.
70. Katiyar S.K., Bihari S., Prakash S., et al. Arandomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008, 12:139-145.
71. Parsons L.M., Somoskövi Á., Gutierrez C. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev 2011, 24(2):314-350.
72. Mlambo C.K., et al. Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa. Int J Tuberc Lung Dis 2008, 12:99-104.
73. David H.L. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 1970, 20:810-814.
74. Gillespie S.H. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother 2002, 46:267-274.
75. Andersson D.I., Levin B.R. The biological cost of antibiotic resistance. Curr Opin Microbiol 1999, 2:489-493.
76. Pym A.S., Saint-Joanis B., Cole S.T. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun 2002, 70:4955-4960.
77. Gandhi N.R., et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010, 375:1830-1843.
78. Zignol M., Gemert W., Falzon D. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012, 90(2):111-119D.
79. Angeby K.A., Klintz L., Hoffner S.E. Rapid and inexpensive drug susceptibility testing of Mycobacterium tuberculosis with a nitrate reductase assay. JClin Microbiol 2002, 40:553-555.
80. Moore D.A., et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. NEngl J Med 2006, 355:1539-1550.
81. Minion J., Leung E., Menzies D., et al. Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10:688-698.
82. Dixit P., Singh U., Sharma P., et al. Evaluation of nitrate reduction assay, resazurin microtiter assay and microscopic observation drug susceptibility assay for first line antitubercular drug susceptibility testing of clinical isolates of M. tuberculosis. JMicrobiol Methods 2012, 88:122-126.
83. Angra P.K., et al. Performance of tuberculosis drug susceptibility testing in U.S. laboratories from 1994 to 2008. JClin Microbiol 2012, 50:1233-1239.
84. Ardito F., Posteraro B., Sanguinetti M., et al. Evaluation of BACTEC Mycobacteria Growth Indicator Tube (MGIT 960) automated system for drug susceptibility testing of Mycobacterium tuberculosis. JClin Microbiol 2001, 39:4440-4444.
85. Koh W.J., Ko Y., Kim C.K., et al. Rapid diagnosis of tuberculosis and multidrug resistance using a MGIT 960 system. Ann Lab Med 2012, 32:264-269.
86. Müller B., Borrell S., Rose G., et al. The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends Genet 2012, 10.1016/j.tig.2012.11.005.
87. Ling D.I., Zwerling A.A., Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 2008, 32:1165-1174.
88. Chryssanthou E., Angeby K. The GenoType® MTBDRplus assay for detection of drug resistance in Mycobacterium tuberculosis in Sweden. APMIS 2012, 120:405-409.
89. Anek-Vorapong R., et al. Validation of the GenoType MTBDRplus assay for detection of MDR-TB in a public health laboratory in Thailand. BMC Infect Dis 2010, 10:123.
90. Hillemann D., Rüsch-Gerdes S., Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. JClin Microbiol 2007, 45:2635-2640.
91. Albert H., et al. Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda. BMC Infect Dis 2010, 10:41.
92. Getahun H., Harrington M., O'Brien R., et al. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 2007, 369:2042-2049.
93. Hanrahan C.F., et al. The impact of expanded testing for multidrug resistant tuberculosis using genotype MTBDRplus in South Africa: an observational cohort study. PLoS One 2012, 7:e49898.
94. Boehme C.C., et al. Rapid molecular detection of tuberculosis and rifampin resistance. NEngl J Med 2010, 363:1005-1015.
95. Theron G., et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 2011, 184:132-140.
96. Van Deun A., Wright A., Zignol M., et al. Drug susceptibility testing proficiency in the network of supranational tuberculosis reference laboratories. Int J Tuberc Lung Dis 2011, 15:116-124.
97. Zhou M., et al. Rapid colorimetric testing for pyrazinamide susceptibility of M.tuberculosis by a PCR-based in-vitro synthesized pyrazinamidase method. PLoS One 2011, 6(11):e27654.
98. Chang K.C., Yew W.W., Zhang Y. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob Agents Chemother 2011, 55:4499-4505.
99. Ajbani K., et al. Evaluation of genotype MTBDRsl assay to detect drug resistance associated with fluoroquinolones, aminoglycosides and ethambutol on clinical sediments. PLoS One 2012, 7(11):e49433.
100. Hillemann D., Rüsch-Gerdes S., Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. JClin Microbiol 2009, 47:1767-1772.
101. Miotto P., Bigoni S., Migliori G.B. Early tuberculosis treatment monitoring by Xpert® MTB/RIF. Eur Respir J 2012, 39(5):1269-1271.
102. Lacoma A., et al. GenoType MTBDRsl for molecular detection of second-line-drug and ethambutol resistance in Mycobacterium tuberculosis strains and clinical samples. JClin Microbiol 2012, 50:30-36.
103. Brossier F., Veziris N., Aubry A., et al. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. JClin Microbiol 2010, 48:1683-1689.
104. Ignatyeva O., et al. Detection of resistance to second-line antituberculosis drugs by use of the genotype MTBDRsl assay: a multicenter evaluation and feasibility study. JClin Microbiol 2012, 50:1593-1597.
105. Mukherjee J.S., Rich M.L., Socci A.R., et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004, 363(9407):474-481.
106. Orenstein E.W., et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009, 9:153-161.
107. Rajbhandary S.S., Marks S.M., Bock N.N. Costs of patients hospitalized for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2004, 8:1012-1016.
108. Bloss E., et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis 2010, 14:275-281.
109. WHO Guidelines for the programmatic management of drug-resistant tuberculosis-2011 update 2011, WHO, Geneva.
110. Eang M.T., et al. The multi-step process of building TB/HIV collaboration in Cambodia. Health Res Policy Syst 2012, 10:34.
111. Brostrom R., et al. Islands of hope: building local capacity to manage an outbreak of multidrug-resistant tuberculosis in the Pacific. Am J Public Health 2011, 101:14-18.
112. Perumal R., Padayatchi N., Stiefvater E. The whole is greater than the sum of the parts: recognising missed opportunities for an optimal response to the rapidly maturing TB-HIV co-epidemic in South Africa. BMC Public Health 2009, 9:243.
113. van der Werf M.J., Langendam M.W. Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis. Eur Respir J 2012, 39(6):1511-1519.
114. Menzies N.A., Cohen T., Lin H.H., et al. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med 2012, 9:e1001347.
115. Mitnick C.D., Shin S.S., Seung K.J., et al. Comprehensive treatment of extensively drug-resistant tuberculosis. NEngl J Med 2008, 359(6):563-574.
116. Seung KJ, Satti H. Management of MDR-TB: a field guide.
117. Caminero J.A., World Health Organization, American Thoracic Society, British Thoracic Society Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006, 10:829-837.
118. Gammino V.M., et al. Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects. Int J Tuberc Lung Dis 2011, 15:1315-1322.
119. Mak A., et al. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med 2008, 178:306-312.
120. Johnston J.C., Shahidi N.C., Sadatsafavi M., et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009, 4(9):e6914.
121. Ahuja S.D., et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012, 9:e1001300.
122. Van Deun A., et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010, 182:684-692.
123. Pooran A., Pieterson E., Davids M., et al. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa?. PLoS One 2013, 8:e54587.
124. Schnippel K., Rosen S., Shearer K. Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa. Trop Med Int Health 2013, 18(1):109-116.
125. Resch S.C., Salomon J.A., Murray M., et al. Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med 2006, 3:e241.
126. Suarez P.G., et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002, 359:1980-1989.
127. Hafkin J., et al. Impact of the human immunodeficiency virus on early multidrug-resistant tuberculosis treatment outcomes in Botswana. Int J Tuberc Lung Dis 2013, 10.5588/ijtld.12.0100.
128. Farley J.E., et al. Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. PLoS One 2011, 6:e20436.
129. Seung K.J., et al. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS One 2009, 4:e7186.
130. Wells C.D., et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. JInfect Dis 2007, 196(Suppl 1):S86-S107.
131. Akksilp S., et al. Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. Emerg Infect Dis 2007, 13:1001-1007.
132. Manosuthi W., Chottanapand S., Thongyen S., et al. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. JAcquir Immune Defic Syndr 2006, 43:42-46.
133. dos Santos A.P., et al. Safety and effectiveness of HAART in tuberculosis-HIV co-infected patients in Brazil. Int J Tuberc Lung Dis 2013, 17:192-197.
134. Gandhi N.R., et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368:1575-1580.
135. Palacios E., et al. HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era. Int J Tuberc Lung Dis 2012, 16:348-354.
136. Tato M., et al. Invitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates. Int J Antimicrob Agents 2006, 28:75-78.
137. Cynamon M.H., Klemens S.P., Sharpe C.A. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999, 43(5):1189-1191.
138. Anger H.A., et al. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06. JAntimicrob Chemother 2010, 65:775-783.
139. Condos R., Hadgiangelis N., Leibert E. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 2008, 134(1):187-192.
140. Fortún J., et al. Linezolid for the treatment of multidrug-resistant tuberculosis. JAntimicrob Chemother 2005, 56:180-185.
141. Lee M., Lee J., Carroll M.W., et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. NEngl J Med 2012, 367(16):1508-1518.
142. Gler M.T., Skripconoka V. Delamanid for multidrug-resistant pulmonary tuberculosis. NEngl J Med 2012, 366(23):2151-2160.
143. Wallis R.S., et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010, 375:1920-1937.
144. Holtz T.H., et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006, 144:650-659.
145. Diacon A.H., Pym A., Grobusch M. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. NEngl J Med 2009, 360(23):2397-2405.
146. Diacon A.H., et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012, 380:986-993.
147. Iseman M.D., Madsen L., Goble M., et al. Surgical intervention in the treatment of pulmonary disease caused by drug-resistant Mycobacterium tuberculosis. Am Rev Respir Dis 1990, 141:623-625.
148. Rizzi A., et al. Results of surgical management of tuberculosis: experience in 206 patients undergoing operation. Ann Thorac Surg 1995, 59:896-900.
149. Man M.A., Nicolau D. Surgical treatment to increase the success rate of multidrug-resistant tuberculosis. Eur J Cardiothorac Surg 2012, 42:e9-e12.
150. Sung S.W., et al. Surgery increased the chance of cure in multi-drug resistant pulmonary tuberculosis. Eur J Cardiothorac Surg 1999, 16:187-193.
151. Shiraishi Y., Katsuragi N., Kita H., et al. Different morbidity after pneumonectomy: multidrug-resistant tuberculosis versus non-tuberculous mycobacterial infection. Interact Cardiovasc Thorac Surg 2010, 11:429-432.
152. Yew W.W., Leung C.C. Management of multidrug-resistant tuberculosis: update 2007. Respirology 2008, 13:21-46.
153. Udwadia Z.F. MDR, XDR, TDR tuberculosis: ominous progression. Thorax 2012, 67(4):286-288.
154. Migliori G.B., De Iaco G., Besozzi G., et al. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007, 12:E070517.1.
155. Velayati A.A., et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009, 136:420-425.
156. Shah N.S., et al. Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa. Emerg Infect Dis 2011, 17:510-513.
157. Kim S.J. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 2005, 25:564-569.
158. Jacobson K.R., Tierney D.B., Jeon C.Y., et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010, 51:6-14.
159. Shah N.S., et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007, 13:380-387.
160. Cegielski P., et al. Challenges and controversies in defining totally drug-resistant tuberculosis. Emerg Infect Dis 2012, 18:e2.
161. Drug-resistant tuberculosis. (World Health Organization). Available at: Accessed on February 1, 2013. http://www.who.int/tb/challenges/mdr/tdrfaqs/en/index.html.
162. Brooks S.M., Lassiter N.L., Young E.C. Apilot study concerning the infection risk of sputum positive tuberculosis patients on chemotherapy. Am Rev Respir Dis 1973, 108:799-804.
163. Gunnels J.J., Bates J.H., Swindoll H. Infectivity of sputum-positive tuberculous patients on chemotherapy. Am Rev Respir Dis 1974, 109:323-330.
164. Jensen P.A., Lambert L.A., Iademarco M.F., CDC, et al. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005, 54:1-141.
165. Cox H.S., Sibilia C., Feuerriegel S., et al. Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis. NEngl J Med 2008, 359(22):2398-2400.
166. Shin S.S., et al. Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med 2010, 182:426-432.
167. Gelmanova I.Y., et al. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bull World Health Organ 2007, 85:703-711.
168. Nodieva A., et al. Recent nosocomial transmission and genotypes of multidrug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2010, 14:427-433.
169. Moro M.L., et al. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. Italian Multidrug-Resistant Tuberculosis Outbreak Study Group. AIDS 1998, 12:1095-1102.
170. Gandhi N.R., et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010, 181:80-86.
171. Edlin B.R., et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. NEngl J Med 1992, 326:1514-1521.
172. Frieden T.R., et al. Amulti-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996, 276:1229-1235.
173. Rullán J.V., et al. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in Spain. Emerg Infect Dis 1996, 2:125-129.
174. Frieden T.R., Fujiwara P.I., Washko R.M., et al. Tuberculosis in New York City-turning the tide. NEngl J Med 1995, 333:229-233.
175. Wenger P.N., et al. Control of nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis among healthcare workers and HIV-infected patients. Lancet 1995, 345:235-240.
176. Maloney S.A., et al. Efficacy of control measures in preventing nosocomial transmission of multidrug-resistant tuberculosis to patients and health care workers. Ann Intern Med 1995, 122:90-95.
177. Kangovi S., Mukherjee J., Bohmer R., et al. Aclassification and meta-analysis of community-based directly observed therapy programs for tuberculosis treatment in developing countries. JCommunity Health 2009, 34:506-513.
178. Shin S., et al. Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience. Soc Sci Med 2004, 59:1529-1539.
179. Farmer P., Kim J.Y. Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus". BMJ 1998, 317:671-674.
180. Wandwalo E., Kapalata N., Egwaga S., et al. Effectiveness of community-based directly observed treatment for tuberculosis in an urban setting in Tanzania: a randomised controlled trial. Int J Tuberc Lung Dis 2004, 8:1248-1254.
181. Nardell E., Dharmadhikari A. Turning off the spigot: reducing drug-resistant tuberculosis transmission in resource-limited settings. Int J Tuberc Lung Dis 2010, 14:1233-1243.
182. Gandhi N.R., et al. Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa. JInfect Dis 2013, 207:9-17.
183. Riley R.L. Airborne infection. Am J Med 1974, 57:466-475.
184. Wells W.F., Ratcliffe H.L., Grumb C. On the mechanics of droplet nuclei infection; quantitative experimental air-borne tuberculosis in rabbits. Am J Hyg 1948, 47:11-28.
185. Dharmadhikari A.S., et al. Surgical face masks worn by patients with multidrug-resistant tuberculosis: impact on infectivity of air on a hospital ward. Am J Respir Crit Care Med 2012, 185:1104-1109.
186. Escombe A.R., et al. Tuberculosis transmission risk and infection control in a hospital emergency department in Lima, Peru. Int J Tuberc Lung Dis 2010, 14:1120-1126.
187. O'Donnell M.R., et al. High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med 2010, 153:516-522.
188. Padayatchi N., Daftary A., Moodley T., et al. Case series of the long-term psychosocial impact of drug-resistant tuberculosis in HIV-negative medical doctors. Int J Tuberc Lung Dis 2010, 14:960-966.
189. Harrington M. Health systems failing health workers: time for a change. Int J Tuberc Lung Dis 2010, 14:935-936.
190. Kanjee Z., Catterick K., Moll A.P., et al. Tuberculosis infection control in rural South Africa: survey of knowledge, attitude and practice in hospital staff. JHosp Infect 2011, 79:333-338.
191. Sutton P.M., Nicas M., Harrison R.J. Tuberculosis isolation: comparison of written procedures and actual practices in three California hospitals. Infect Control Hosp Epidemiol 2000, 21:28-32.
192. Bratcher D.F., Stover B.H., Lane N.E., et al. Compliance with national recommendations for tuberculosis screening and immunization of healthcare workers in a children's hospital. Infect Control Hosp Epidemiol 2000, 21:338-340.
193. Stroud L.A., et al. Evaluation of infection control measures in preventing the nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in a New York City hospital. Infect Control Hosp Epidemiol 1995, 16:141-147.
194. Upshur R. Apocalypse or redemption: responding to extensively drug-resistant tuberculosis. Bull World Health Organ 2009, 87:481-483.